Payment overview · 2025
General Payments
$169.58
8 reported records · 7 companies
Healthcare provider profile · identity verified
Michael S Schorr, M.D.
Allopathic & Osteopathic Physicians|General Practice · PATTERSON, CA · NPI 1508922089
Verified facts
What the public records show
CMS Open Payments records show Michael S Schorr, M.D. received $169.58 in general payments during 2025 across 8 reported records.
Phathom Pharmaceuticals, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.64 | 20.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.26 | 19.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.70 | 16.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.47 | 11.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.12 | 11.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.90 | 11.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.49 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.58 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 153 |
| Lisinopril | Lisinopril | 496 | 122 |
| Metformin Hcl | Metformin Hcl | 470 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 75 |
| Simvastatin | Simvastatin | 340 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 82 |
| Gabapentin | Gabapentin | 276 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 65 |
| Furosemide | Furosemide | 224 | 51 |
| Omeprazole | Omeprazole | 209 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 195 | 49 |
| Losartan Potassium | Losartan Potassium | 194 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 52 |
| Baclofen | Baclofen | 168 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 49 |
| Ozempic | Semaglutide | 132 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 27 |
| Jardiance | Empagliflozin | 128 | 27 |
| Meloxicam | Meloxicam | 107 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 106 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 19 |
| Trazodone Hcl | Trazodone Hcl | 89 | 27 |
| Alendronate Sodium | Alendronate Sodium | 87 | 25 |
| Spironolactone | Spironolactone | 87 | 17 |
| Carvedilol | Carvedilol | 84 | 22 |
| Ezetimibe | Ezetimibe | 84 | 18 |
| Allopurinol | Allopurinol | 83 | 18 |
| Glimepiride | Glimepiride | 81 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 22 |
| Atenolol | Atenolol | 77 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 75 | 18 |
| Metformin Hcl Er | Metformin Hcl | 74 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 30 |
| Potassium Chloride | Potassium Chloride | 73 | 15 |
| Ibuprofen | Ibuprofen | 72 | 37 |
| Eliquis | Apixaban | 71 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 14 |
| Donepezil Hcl | Donepezil Hcl | 69 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 11 |
| Azithromycin | Azithromycin | 64 | 58 |
| Alprazolam | Alprazolam | 58 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 13 |
| Bupropion Xl | Bupropion Hcl | 55 | 11 |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 32 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 30 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Acarbose | Acarbose | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 33 |
| Topiramate | Topiramate | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 24 |
| Famotidine | Famotidine | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | 16 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | 11 |
| Nystatin | Nystatin | 29 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Finasteride | Finasteride | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Linzess | Linaclotide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Kerendia | Finerenone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Pacerone | Amiodarone Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.58 · 8 records | Phathom Pharmaceuticals, Inc. | ABRYSVO, COMIRNATY, Kerendia, Korlym, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error